An interventional study of MERIT in Diagnosis of Schizophrenia Spectrum Disorders, sponsored by Bar-Ilan University, Israel. Completed at 1 site in Israel. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by Bar-Ilan University, Israel · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Schizophrenia with a site in Israel — 3 open to participants now, 4 under way, none of them phase 3. Schizophrenia · Israel.
Among the 112 studies in Schizophrenia with a site in Israel, this one is the 43rd largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2018, is one of 30 with no phase, and was the 95th registered.
3,567 studies on the registry are indexed under Schizophrenia; 492 are open to participants now.
Browse Schizophrenia studies →3 of the 112 studies in Schizophrenia with a site in Israel are open now. Recruiting first, the newest first:
Amit Lotan · Sites in Israel
Ages 18–40 · Healthy volunteers
Mapi Pharma Ltd. · Sites in Israel, India
Ages 18–64
Sheba Medical Center · Sites in Israel
Ages 18+ · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 29 · Phase 4 15
First in 2000; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 71 across 2,945 interventional studies indexed under Schizophrenia.
Median enrollment 53 across the 88 interventional studies, 100 across the 22 observational. Of the 61 that completed or were terminated, 13 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 112 have an industry lead sponsor. The 10 most frequent:
Bar-Ilan University, Israel is the lead sponsor of 21 studies on the registry; 4 are open to participants now.
Bar-Ilan University, Israel has 2 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
1 of the studies in Schizophrenia with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 112 studies in Schizophrenia with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with schizophrenia spectrum disorders are faced with significant metacognitive impairments that include difficulties in their ability to form complex representations of the self and others. These impairments are associated with increased symptoms, impaired subjective self-experiences, and lower social functioning. As a result, interventions that enhance metacognitive capacity have been recently developed and explored. One of these interventions is Metacognitive Reflection and Insight Therapy (MERIT; Lysaker et al., 2014). MERIT is an integrative model of psychotherapy that seeks to promote holistic metacognitive capacity and consequently increase a positive sense of agency and sense of meaning in life among clients with schizophrenia. Several case studies (including in Bar-Ilan's community clinic), as well as a recent pilot study, showed increased metacognitive abilities and a decrease in symptoms following MERIT. The current study will explore both the effectiveness and the change mechanisms that underlie MERIT interventon among clients diagnosed with schizophrenia spectrum disorders, via both pre- and post-measures of the intervention's outcome and session-by-session estimations of the therapeutic process.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: MERIT
Behavioral: MERIT
Metacognitive Reflection and Insight Therapy
Metacognition Assessment Scale-Abbreviated (MAS-A)
The Metacognition Assessment Scale-Abbreviated (MAS-A) is a rating scale used to assess metacognitive abilities in individuals, particularly those with psychiatric conditions. The scale consists of four domains that reflect one's ability to understand different mental phenomena and use this understanding in order to cope with psychological challenges. Higher scores indicate a higher complexity of functions and ideas in each domain, i.e. higher values represent a better outcome. The four scales/domains: 1. self-reflectivity (min 1 to max 9) ; 2. understanding of the other's mind (min 1 to max 7) ; 3. decentration (min 1 to max 3) ; 4. mastery (min 1 to max 9). The total score is the sum of the ratings in each subscale. Thus, the total score can be ranged from 4 (min) to 28 (max), when higher values represent a better outcome.
Time frame: Prior to the begining of the therapy (baseline, pre-treatment), and again at the end of the therapy (six months later, post-treatment)
Participants were 35 adults diagnosed with of schizophrenia /schizoaffective disorder. Exclusion criteria: intellectual disability, neurological disorders, substance use problems, acute psychosis, and risk for suicidal behavior, based on the intake interview. The study used a delayed randomized controlled trial design to examine the therapeutic benefits of MERIT delivered in a community clinic at Bar-Ilan University.
| Milestone | Treatment Group | Delayed Treatment Control Group |
|---|---|---|
| Started | 31 | 23 |
| Completed | 21 | 14 |
| Not completed | 10 | 9 |
The Metacognition Assessment Scale-Abbreviated (MAS-A) is a rating scale used to assess metacognitive abilities in individuals, particularly those with psychiatric conditions. The scale consists of four domains that reflect one's ability to understand different mental phenomena and use this understanding in order to cope with psychological challenges. Higher scores indicate a higher complexity of functions and ideas in each domain, i.e. higher values represent a better outcome. The four scales/domains: 1. self-reflectivity (min 1 to max 9) ; 2. understanding of the other's mind (min 1 to max 7) ; 3. decentration (min 1 to max 3) ; 4. mastery (min 1 to max 9). The total score is the sum of the ratings in each subscale. Thus, the total score can be ranged from 4 (min) to 28 (max), when higher values represent a better outcome.
| score on a scale | Delayed Treatment Control Group | Treatment Group |
|---|---|---|
| Pre (treatment/waiting period) | 11.53 ± 3.7 | 14.22 ± 2.75 |
| Post (treatment/waiting period) | 14.22 ± 3.4 | 14.25 ± 4.2 |
Collected over 2 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Group | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| Delayed Treatment Control Group | 0/23 (0%) | 0/23 (0%) | 0/23 (0%) |
| Age, Continuous(years) | Treatment Group | Delayed Treatment Control Group | Total |
|---|---|---|---|
| Mean | 39 ± 10.63 | 40.5 ± 8.71 | 39.6 ± 9.74 |
| Sex: Female, Male(Participants) | Treatment Group | Delayed Treatment Control Group | Total |
|---|---|---|---|
| Female | 18 | 14 | 32 |
| Male | 13 | 9 | 22 |
| Race and Ethnicity Not Collected(Participants) | Treatment Group | Delayed Treatment Control Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Treatment Group | Delayed Treatment Control Group | Total |
|---|---|---|---|
| Israel | 21 | 14 | 35 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Mar 2021, 36 months.
Results were first posted in Mar 2025, 4 years after primary completion.
Of 755 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 36 months is close to that.
Counting every sponsor, half of 768 studies reached it within 33 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bar-Ilan University, Israel